1. Home
  2. EARN vs GNFT Comparison

EARN vs GNFT Comparison

Compare EARN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EARN
  • GNFT
  • Stock Information
  • Founded
  • EARN 2012
  • GNFT 1999
  • Country
  • EARN United States
  • GNFT France
  • Employees
  • EARN N/A
  • GNFT N/A
  • Industry
  • EARN Real Estate Investment Trusts
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EARN Real Estate
  • GNFT Health Care
  • Exchange
  • EARN Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • EARN 189.7M
  • GNFT 216.7M
  • IPO Year
  • EARN 2013
  • GNFT 2019
  • Fundamental
  • Price
  • EARN $5.09
  • GNFT $3.86
  • Analyst Decision
  • EARN Buy
  • GNFT Strong Buy
  • Analyst Count
  • EARN 2
  • GNFT 2
  • Target Price
  • EARN $5.88
  • GNFT $10.00
  • AVG Volume (30 Days)
  • EARN 356.7K
  • GNFT 6.4K
  • Earning Date
  • EARN 11-19-2025
  • GNFT 09-22-2025
  • Dividend Yield
  • EARN 18.86%
  • GNFT N/A
  • EPS Growth
  • EARN N/A
  • GNFT N/A
  • EPS
  • EARN N/A
  • GNFT N/A
  • Revenue
  • EARN $35,893,000.00
  • GNFT $52,994,715.00
  • Revenue This Year
  • EARN N/A
  • GNFT $3.14
  • Revenue Next Year
  • EARN $15.93
  • GNFT N/A
  • P/E Ratio
  • EARN N/A
  • GNFT N/A
  • Revenue Growth
  • EARN 43.30
  • GNFT N/A
  • 52 Week Low
  • EARN $4.33
  • GNFT $2.55
  • 52 Week High
  • EARN $6.99
  • GNFT $6.03
  • Technical
  • Relative Strength Index (RSI)
  • EARN 35.22
  • GNFT 41.41
  • Support Level
  • EARN $5.10
  • GNFT $4.07
  • Resistance Level
  • EARN $5.40
  • GNFT $4.24
  • Average True Range (ATR)
  • EARN 0.09
  • GNFT 0.18
  • MACD
  • EARN 0.01
  • GNFT -0.02
  • Stochastic Oscillator
  • EARN 20.52
  • GNFT 28.11

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: